How to cite item

Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors

  
@article{APS9417,
	author = {Tong-chao Liu and Xia Peng and Yu-chi Ma and Yin-chun Ji and Dan-qi Chen and Ming-yue Zheng and Dong-mei Zhao and Mao-sheng Cheng and Mei-yu Geng and Jing-kang Shen and Jing Ai and Bing Xiong},
	title = {Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors},
	journal = {Acta Pharmacologica Sinica},
	volume = {37},
	number = {5},
	year = {2017},
	keywords = {},
	abstract = {Aim: Aberrant c-Met activation plays a critical role in cancer formation, progression and dissemination, as well as in development of resistance to anticancer drugs. Therefore, c-Met has emerged as an attractive target for cancer therapy. The aim of this study was to develop new c-Met inhibitors and elaborate the structure-activity relationships of identified inhibitors.
Methods: Based on the predicted binding modes of Compounds5 and 14 in docking studies, a new series of c-Met inhibitor-harboring 3-((1H-pyrrolo[3,2-c]pyridin-1-yl)sulfonyl)imidazo[1,2-a]pyridine scaffolds was discovered. Potent inhibitors were identified through extensive optimizations combined with enzymatic and cellular assays. A promising compound was further investigated in regard to its selectivity, its effects on c-Met signaling, cell proliferation and cell scattering in vitro.
Results: The most potent Compound 31 inhibited c-Met kinase activity with an IC50 value of 12.8 nmol/L, which was >78-fold higher than those of a panel of 16 different tyrosine kinases. Compound 31 (8, 40, 200 nmol/L) dose-dependently inhibited the phosphorylation of c-Met and its key downstream Akt and ERK signaling cascades in c-Met aberrant human EBC-1 cancer cells. In 12 human cancer cell lines harboring different background levels of c-Met expression/activation, Compound 31 potently inhibited c-Met-driven cell proliferation. Furthermore, Compound 31 dose-dependently impaired c-Met-mediated cell scattering of MDCK cells.
Conclusion: This series of c-Met inhibitors is a promising lead for development of novel anticancer drugs.},
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/9417}
}